IRYCIS
Biomarkers to identify ocrelizumab good drug responders in patients with PP multiple sclerosis
Biomarkers
Autoimmune & Inflammation
Central Nervous System
Primary progressive multiple sclerosis
3Clinical validation,
2Preclinical Validation,
1R+D